Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors.

Trial Profile

Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Carboplatin
  • Indications Ovarian cancer; Uterine cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Feb 2012 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
    • 25 Oct 2011 Additional lead trial center identified and company added in the association field as reported by ClinicalTrials.gov.
    • 07 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top